TGK Stock Chart & Stats
€5.90
€0.00(0.00%)
At close: 4:00 PM EDT
€5.90
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.90 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€37.17M
Enterprise Value€44.77
Total Cash (Recent Filing)€3.08M
Total Debt (Recent Filing)€3.34M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding1,790,188
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.35
Revenue Forecast (FY)€68.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRecord quarterly revenue and strong year-over-year growth indicate expanding demand for Precipio’s cancer diagnostics. Continued top-line momentum can improve operating leverage, support investment in commercialization, and strengthen the company’s ability to scale its laboratory and product businesses.
Cash GenerationPositive operating cash flow and a growing cash balance represent a meaningful improvement from prior periods of negative cash generation. Internally funded operations provide greater financial flexibility for commercialization and reduce near-term reliance on external capital.
Diagnostic Product InnovationThe integrated laboratory-to-product model supports development and real-world validation of differentiated diagnostics. Faster AML results may improve clinical utility and help Precipio attract domestic and international interest, marketing collaborations, and clinical-study opportunities.
Bears Say
Persistent UnprofitabilityDespite revenue growth and improved cash flow, Precipio has not yet established consistent GAAP profitability. Continued operating and net losses can limit reinvestment capacity, reduce balance-sheet efficiency, and make future performance dependent on sustained execution and revenue expansion.
Limited Pathology GrowthThe core pathology business showed limited sequential expansion while resources shifted toward product commercialization. If pathology growth remains modest, overall performance may rely more heavily on newer product revenue, increasing the importance of successful commercialization.
Pipeline Conversion RiskA larger distributor and customer pipeline has not yet guaranteed recurring revenue. Converting qualified prospects into active accounts requires effective execution, and failure to do so could slow growth, delay operating leverage, and leave recent commercial investments underutilized.
Precipio News
TGK FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was €5.90 and its highest was €5.90 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is €37.17M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Nov 16, 2026 which is in 50 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Aug 14, 2026. The company reported -€0.107 earnings per share for the quarter.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,790,188 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -€0.107 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in DE:TGK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:TGK Sentiment 75%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
TGK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial improvements: record quarterly revenue (> $7M), strong product revenue acceleration (+35% sequential, +21% vs prior record), positive adjusted EBITDA (~$400K) and $700K operating cash generation leading to a >$3M cash balance. These positives are tempered by modest pathology sequential growth, prior distributor complexity that slowed past ramping, quarter-to-quarter timing/seasonality effects, noted execution risk to convert the expanded pipeline, and an unexplained spike in share trading. On balance, the company emphasized organic improvement and execution plans to sustain growth.View all DE:TGK earnings summaries